Drugs / Umbilical Cord Blood Derived MAK Immune Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05240690 | Feb 2022 → Dec 2023 | carcinoma of liver and intrahepatic biliary tract, pancreas disorder | Zhou Fuxiang | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umbilical Cord Blood Derived MAK Immune Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05240690 ↗ |
| Route | Intravenous | “Intravenous drip” NCT05240690 ↗ |